Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

27.82 -0.05 (-0.18%)
Streaming Delayed Price Updated: 11:01 AM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug
The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million. 
Via Stocktwits
Topics Earnings
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
 
Via Benzinga
Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide
TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global growth. 
Via Benzinga
TG Therapeutics Q2 Revenue Up 91%
Via The Motley Fool
Topics Intellectual Property
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook
The company makes a multiple sclerosis treatment called Briumvi that rivals a drug from Roche. 
Via Investor's Business Daily
Earnings Scheduled For August 4, 2025
 
Via Benzinga
What's Next: TG Therapeutics's Earnings Preview
 
Via Benzinga
Earnings Scheduled For May 5, 2025
 
Via Benzinga
Why TG Therapeutics Stock Was Soaring This Week
Via The Motley Fool
Traders are paying attention to the gapping stocks in Monday's session.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
TG Therapeutics Inc (NASDAQ:TGTX) Reports Mixed Q2 2025 Results, Raises Full-Year BRIUMVI Revenue Guidance
TG Therapeutics reported mixed Q2 2025 results, missing revenue and EPS estimates but raising full-year BRIUMVI sales guidance. Shares dipped slightly as investors weighed the outlook. 
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) – A High Growth Momentum Stock with Strong Technical Setup
TG THERAPEUTICS INC (NASDAQ:TGTX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. The stock has solid revenue growth, improving margins,... 
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High-Growth Stock Meeting Minervini's Trend Template
TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal... 
Via Chartmill
Cramer Backs This Mining Giant After $1.6B Bet
Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth. 
Via Benzinga
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High Growth Momentum Stock with Strong Technical Setup
TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors. 
Via Chartmill
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook
Investors are optimistic about the company’s prospects, particularly in the multiple sclerosis market, despite challenges from competitors. 
Via Stocktwits
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025. 
Via Benzinga
Why TG Therapeutics Stock Was Tumbling Today
Via The Motley Fool
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
 
Via Benzinga
TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic
The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million. 
Via Stocktwits
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX)
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing? 
Via Chartmill
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate 
Via Chartmill
Exploring high growth characteristics of TG THERAPEUTICS INC (NASDAQ:TGTX).
UA fundamental and technical analysis of (NASDAQ:TGTX): nlocking the high Growth Potential of TG THERAPEUTICS INC (NASDAQ:TGTX). 
Via Chartmill
Price Over Earnings Overview: TG Therapeutics
 
Via Benzinga
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX)
Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:TGTX). 
Via Chartmill
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
The companies both have drugs that treat relapsing forms of multiple sclerosis. 
Via Investor's Business Daily
Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher
TG Therapeutics has broken an important resistance level. There is a good chance that they will continue to move higher. 
Via Benzinga
How does TG THERAPEUTICS INC (NASDAQ:TGTX) stack up against Mark Minervini’s strategy?
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing? 
Via Chartmill
TG THERAPEUTICS INC (NASDAQ:TGTX), a growth stock which is not overvalued.
Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?
Top mid-cap stocks jumped up to 23.87%. Some reasons include strong gold/silver, better financial results, and market strength. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.